AstraZeneca, on BMS' heels, scores lung cancer win with Imfinzi combos

After a few long years of watching from the sidelines as its rivals dove into immuno-oncology’s most coveted market, AstraZeneca finally has a study win in previously untreated non-small cell lung cancer. Monday, the British drugmaker said a combination of Imfinzi, CTLA4 candidate tremelimumab and chemo outperformed solo chemo at keeping patients’ cancer from progressing.